Open an account

Bristol-Myers Squibb

BMY · NYSE

$61.68+$2.85 (+4.84%)TodayMarket closed ·
Prev close $58.83

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 32,500 full-time employees. The company is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).

Employees
32,500
Headquarters
Princeton, New Jersey
Listed
Mar 17, 1980
Sector
Health Care
Industry
Pharmaceuticals
Website
bms.com

BMY key statistics

Market cap
120.17B
Price-earnings ratio
12.96
Dividend yield
6.34%
Average volume
13.55M
Volume
9.28M
Open price
$59.93
High today
$61.82
Low today
$59.83
52 Week high
$68.64
52 Week low
$42.52

Bristol-Myers Squibb (BMY) at a glance

As of Oct 20, 2026, Bristol-Myers Squibb (BMY) shares are priced at $61.68, giving the company a market cap of 120.17B, a price-to-earnings ratio of 12.96 and a dividend yield of 6.34%.

Today the stock has traded between $59.83 and $61.82. The current price is 3.1% above the day's low and 0.2% below its high.

Volume so far is 9.28M shares, below the average of 13.55M shares a day.

Over the past year Bristol-Myers Squibb has ranged from $42.52 to $68.64, and now sits 73% of the way up that range.

Bristol-Myers Squibb met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported $2.04 per share against an estimate of $1.60.

The average analyst price target is $68.14, 10.5% above the current price, from 18 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

44%of 18 analyst ratings say Buy
  • Buy44.4%
  • Hold50.0%
  • Sell5.6%
Price target · 27 analystsAvg $68.14
Low
$40.40
Now
$61.68
High
$86.10

BMY earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 18.0% on average.

  1. Q3 FY24: reported $1.80 per share against an estimate of $1.51
  2. Q4 FY24: reported $1.67 per share against an estimate of $1.47
  3. Q1 FY25: reported $1.80 per share against an estimate of $1.51
  4. Q2 FY25: reported $1.46 per share against an estimate of $1.08
  5. Q3 FY25: reported $1.63 per share against an estimate of $1.52
  6. Q4 FY25: reported $1.26 per share against an estimate of $1.13
  7. Q1 FY26: reported $1.58 per share against an estimate of $1.43
  8. Q2 FY26: reported $2.04 per share against an estimate of $1.60

BMY news

  • Press releaseBusiness Wire

    Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026

  • 10 Health Care Stocks With Whale Alerts In Today’s Session

  • Vandana Singh

    Why Is Contineum Therapeutics Stock Falling Monday?

  • Vandana Singh

    Why Is Bristol Myers Squibb Stock Gaining Monday?

  • Press releaseBusiness Wire

    Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs

  • Press releaseBusiness Wire

    Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint

  • Vandana Singh

    Bristol Myers Squibb’s Zenbexus Delivers Major Blood Cancer Win, Cuts Progression Risk 51%

  • Press releaseBusiness Wire

    Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3...

Similar companies

Companies in the same industry as Bristol-Myers Squibb

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.